192 results on '"Morimoto, Kenji"'
Search Results
2. Efficacy and Safety of Docetaxel plus Ramucirumab for Patients with Pretreated Advanced or Recurrent Non-small Cell Lung Cancer: Focus on Older Patients
3. Chemoimmunotherapy Versus Pembrolizumab as a First-Line Treatment for Patients with Advanced Non-small Cell Lung Cancer and High PD-L1 Expression: Focus on the Role of Performance Status
4. Triple combination therapy comprising osimertinib, an AXL inhibitor, and an FGFR inhibitor improves the efficacy of EGFR-mutated non-small cell lung cancer
5. Clinical Efficacy and Safety of First- or Second-Generation EGFR-TKIs after Osimertinib Resistance for EGFR Mutated Lung Cancer: A Prospective Exploratory Study
6. AXL signal mediates adaptive resistance to KRAS G12C inhibitors in KRAS G12C-mutant tumor cells
7. Adaptive resistance to lorlatinib via EGFR signaling in ALK-rearranged lung cancer
8. Prospective Observational Study Evaluating the Prognostic Value of the G8 Screening Tool for Extensive-Stage Small Cell Lung Cancer Patients Who Received Programmed Death-Ligand 1 Inhibitor plus Platinum–Etoposide Chemotherapy
9. Predictive value of p53 and AXL immunostaining for the efficacy of immune checkpoint inhibitor-based therapy after osimertinib treatment in patients with epidermal growth factor-mutant non-small cell lung cancer
10. Comparing Three Different Anti–Programmed Death-Ligand 1 Antibodies in Immunohistochemical Evaluation of Combined Chemoimmunotherapy Response in Patients With NSCLC: A Prospective Study
11. Cubic-Tetragonal Phase Transformations In the ZrO2-CeO2 System
12. A phase 2 trial of durvalumab treatment following radiation monotherapy in patients with non-small cell lung cancer ineligible for stage III chemoradiotherapy: The SPIRAL-RT study
13. Impact of maintenance therapy following induction immunochemotherapy for untreated advanced non-small cell lung cancer patients
14. Analysis of Tumor Heterogeneity Through AXL Activation in Primary Resistance to EGFR Tyrosine Kinase Inhibitors
15. Early Tumor Shrinkage as a Predictor of Favorable Treatment Outcomes in Patients With Extensive-Stage SCLC Who Received Programmed Cell Death-Ligand 1 Inhibitor Plus Platinum-Etoposide Chemotherapy: A Prospective Observational Study
16. TTF-1 Expression and Clinical Outcomes of Combined Chemoimmunotherapy in Patients With Advanced Lung Adenocarcinoma: A Prospective Observational Study
17. Significance of localized expression of full-length growth differentiation factor-15 in cachexia of advanced non-small cell lung cancer
18. Early discontinuation of induction therapy in chemoimmunotherapy as an effective alternative to the standard regimen in patients with non-small cell lung cancer: a retrospective study
19. A Real-World Analysis of Immune Checkpoint Inhibitor-Based Therapy After Osimertinib Treatment in Patients With EGFR-Mutant NSCLC
20. HER3 activation contributes toward the emergence of ALK inhibitor-tolerant cells in ALK-rearranged lung cancer with mesenchymal features
21. Automated Rust Removal: Rust Detection and Visual Servo Control
22. Clinical significance of chronic pulmonary aspergillosis in lung cancer patients undergoing anticancer drug therapy.
23. Figure S7 from Effects of Combined Therapeutic Targeting of AXL and ATR on Pleural Mesothelioma Cells
24. Data from Effects of Combined Therapeutic Targeting of AXL and ATR on Pleural Mesothelioma Cells
25. Supplementary Table2 from Effects of Combined Therapeutic Targeting of AXL and ATR on Pleural Mesothelioma Cells
26. Clinical impact of pembrolizumab combined with chemotherapy in elderly patients with advanced non-small-cell lung cancer
27. Prospective Observational Study of Ramucirumab Plus Docetaxel After Combined Chemoimmunotherapy in Patients With Non-Small-Cell Lung Cancer
28. Nationwide data from comprehensive genomic profiling assays for detecting driver oncogenes in non‐small cell lung cancer.
29. Effects of Combined Therapeutic Targeting of AXL and ATR on Pleural Mesothelioma Cells
30. MO57-6 Comprehensive genomic profiling is effective in determining treatment decisions for advanced solid tumors patients
31. MO38-3 EGFR activation elicited adaptive resistance to lorlatinib in ALK-rearranged non-small cell lung cancer cells
32. The landscape of immune therapy in vulnerable patients with advanced non-small cell lung cancer: a narrative review
33. Recurrence of Large-Vessel Vasculitis Induced by Multiple Types of Granulocyte Colony-Stimulating Factor Preparation in Patient with Large-Cell Neuroendocrine Lung Carcinoma: A Case Report
34. Endobronchial metastasis of hepatocellular carcinoma treated with Lenvatinib: A case report
35. Concomitant Proton Pump Inhibitor Use With Pembrolizumab Monotherapy vs Immune Checkpoint Inhibitor Plus Chemotherapy in Patients With Non−Small Cell Lung Cancer
36. Abstract 4015: EGFR activation via c-Jun axis promotes adaptive resistance to third generation ALK-TKI lorlatinib in ALK-rearranged non-small cell lung cancer cells
37. Abstract 6222: Clinical impact of p53 and AXL immunostaining on the efficacy of immune checkpoint inhibitor-based therapy after osimertinib treatment in patients with epidermal growth factor mutant non-small cell lung cancer
38. Age-Stratified Analysis of First-Line Chemoimmunotherapy for Extensive-Stage Small Cell Lung Cancer: Real-World Evidence from a Multicenter Retrospective Study
39. Comparison of the prognosis of symptomatic cerebral infarction and pulmonary embolism in patients with advanced non‐small cell lung cancer
40. Rationale and design of phase II clinical trial of dual inhibition with ramucirumab and erlotinib in EGFR exon 19 deletion-positive treatment-naïve non-small cell lung cancer with high PD-L1 expression (SPIRAL-3D study)
41. 367: SEVERE AUTOIMMUNE HEMOLYTIC ANEMIA IN A YOUNG CHILD WITH ACTIVE COVID-19 INFECTION
42. High levels of AXL expression in untreatedEGFR‐mutated non‐small cell lung cancer negatively impacts the use of osimertinib
43. Corrigendum to “A real-world study on the safety of the extended dosing schedule for nivolumab and pembrolizumab in patients with solid tumors” [Int. Immunopharmacol. 108 (2022) 108775]
44. Localized expression and role of full-length growth differentiation factor 15 in non-small cell lung cancer
45. Adaptive Resistance to Lorlatinib via EGFR Signaling in ALK-rearranged Lung Cancer
46. Efficacy and Safety of Paclitaxel/nab-paclitaxel Chemotherapy for Patients With Relapsed Small Cell Lung Cancer
47. Pembrolizumab monotherapy for untreated PD-L1-Positive non-small cell lung cancer in the elderly or those with poor performance status: A prospective observational study
48. Efficacy and Safety of Programmed Death-Ligand 1 Inhibitor Plus Platinum-Etoposide Chemotherapy in Patients With Extensive-Stage SCLC: A Prospective Observational Study
49. A real-world study on the safety of the extended dosing schedule for nivolumab and pembrolizumab in patients with solid tumors
50. Venetoclax and Azacitidine in the Treatment of NPM1 -Mutated Donor Cell–Derived Leukemia in a Patient With Fanconi Anemia: Case Report and Literature Review.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.